LXEO vs RCKT
LXEO: Lexeo is a clinical-stage genetic medicine company developing gene therapies targeting the genetic root causes of rare cardiovascular diseases like Friedreich ataxia cardiomyopathy. RCKT: Rocket Pharmaceuticals is a clinical-stage biotechnology company developing transformative gene therapies for rare, high-unmet-need genetic disorders.
Side-by-side fundamentals
| Metric | LXEO | RCKT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $4.87 | $3.30 | |
| Market cap as of 2026-07-23 | $365M | $368M | |
| Net margin as of 2026-07-23 | -11991.8% | n/a | |
| Operating margin as of 2026-07-23 | -12408.4% | n/a | |
| ROE as of 2026-07-23 | -47.5% | -70.8% | LXEO higher |
| ROA as of 2026-07-23 | -41.7% | -59.6% | LXEO higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.09 | LXEO lower |
| Beta as of 2026-07-23 | 1.40 | 0.46 | |
| 1-year return as of 2026-07-22 close | +17.7% | -2.1% | LXEO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.